Provided by Tiger Fintech (Singapore) Pte. Ltd.

Haemonetics

64.80
-0.7200-1.10%
Post-market: 61.56-3.2400-5.00%17:58 EDT
Volume:1.16M
Turnover:75.10M
Market Cap:3.26B
PE:25.52
High:65.76
Open:65.33
Low:64.35
Close:65.52
Loading ...

Company Profile

Company Name:
Haemonetics
Exchange:
NYSE
Establishment Date:
1971
Employees:
3657
Office Location:
125 Summer Street,Boston,Massachusetts,United States
Zip Code:
02110
Fax:
- -
Introduction:
Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot including collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.

Directors

Name
Position
Christopher Simon
President and Chief Executive Officer,Director
Charles J. Dockendorff
Independent Director
Claire Pomeroy
Independent Director
Ellen M. Zane
Independent Director,Chair of the Board
Lloyd E. Johnson
Independent Director
Mark W. Kroll
Independent Director
Michael J. Coyle
Independent Director
Robert Abernathy
Independent Director

Shareholders

Name
Position
Christopher Simon
President and Chief Executive Officer,Director
James C. D'Arecca
Executive Vice President, Chief Financial Officer
Josep L. Llorens
Senior Vice President, Global Manufacturing and Supply Chain
Laurie A. Miller
Senior Vice President, Chief Human Resources Officer
Anila Lingamneni
Executive Vice President, Chief Technology Officer
Michelle Basil
Executive Vice President, General Counsel
Roy Galvin
President, Global Plasma and Blood Center
Stewart W. Strong
President, Global Hospital